Fish Oil and Blood Pressure Drug Tested to Prevent Mobility Loss in Seniors

The ENRGISE pilot study addressed a critical question in healthy aging: can anti-inflammatory interventions prevent mobility decline in older adults? Researchers hypothesized that targeting chronic low-grade inflammation might preserve walking ability and prevent disability.

The University of Florida conducted this randomized controlled trial with 289 senior participants over approximately two years. Participants received either omega-3 fish oil, losartan (an ACE receptor blocker typically used for blood pressure), or corn oil placebo. The study specifically measured effects on walking ability and mobility function.

Chronic inflammation increases with age and contributes to muscle weakness, joint problems, and overall physical decline. By testing two different anti-inflammatory approaches—omega-3 fatty acids and losartan—researchers aimed to identify practical interventions that could maintain independence in aging populations.

While detailed results aren't provided in this summary, the completed status indicates the trial successfully gathered data on whether these interventions can meaningfully impact mobility outcomes. Both omega-3s and losartan are widely available and well-tolerated, making them potentially scalable solutions if proven effective.

This research has significant implications for longevity and healthspan. Maintaining mobility is crucial for independence, quality of life, and overall health in later years. If anti-inflammatory interventions can prevent or delay mobility disability, they could help more people age successfully while reducing healthcare costs and improving life satisfaction for millions of seniors.